Huimin CHEN

2024-02-19

After experiencing more than 20 new drug applications (NDA) in MNCs, I hope to help a locally developed innovative drug to achieve NDA at a biotech from 0 to 1.

Last:none

Next:Wenyue MA

Back

Media contact

e-mail:communication@laekna.com

Recommendation

2024-06-26

Laekna Announces First Subject Dosed in Phase I Clinical Trial of LAE102 (a monoclonal antibody against ActRIIA) in China for The Treatment of Obesity
More

RSS Feeds

If you want to know more about Laekna, please fill in the form below and sign up for emails: